CRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
CorMedix Inc. (CRMD) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock lacks clear positive momentum, and while there is potential upside, the financial performance and recent analyst downgrades suggest caution. A hold is recommended until more favorable signals or catalysts emerge.
The MACD is positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 56.961, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 7.274, with resistance at 7.599 and support at 6.95, suggesting limited immediate upside.
The company has demonstrated significant YoY revenue growth (810.22%) in Q3 2025, indicating strong sales momentum. Additionally, the stock has a 60% chance to gain 3.42% in the next month based on historical patterns.
No significant hedge fund or insider activity, and no recent news or congress trading data to act as a catalyst.
In Q3 2025, revenue increased significantly to $104.28M (+810.22% YoY), but net income dropped to -$108.56M (-4009.63% YoY), and EPS fell to -1.26 (-2620.00% YoY). Gross margin declined slightly to 89.26% (-5.05% YoY), reflecting challenges in profitability despite revenue growth.
Analysts have lowered price targets recently (H.C. Wainwright: $13 from $18, RBC Capital: $13 from $22, Truist: $16 from $20) while maintaining Buy or Outperform ratings. This reflects cautious optimism but highlights concerns about the company's future revenue potential.
